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Abstract
Background There is now greater involvement of children
in drug trials to ensure that paediatric medicines are
supported by sound scientific evidence. The safety of the
participating children is of paramount importance. Previous
research shows that these children can suffer moderate and
severe adverse drug reactions (ADRs) in clinical trials, yet
very few of the trials designated a data safety monitoring
board (DSMB) to oversee the trial.
Methods Safety data from a systematic review of paediatric
drug randomised controlled trials (RCTs) published in 2007
were analysed. All reported adverse events (AEs) were
classified and assessed to determine whether an ADR had
been experienced. ADRs were then categorised according
to severity. Each trial report was examined as to whether an
independent DSMB was in place.
Results Of the 582 paediatric drug RCTs analysed, 210 (36%)
reported that a serious AE had occurred, and in 15% mortality
was reported. ADRs were detected in more than half of the
RCTs (305); 66 (11%) were severe, and 79 (14%) were
moderate. Severe ADRs involved a wide range of organ systems
and were frequently associated with cytotoxic drugs, antipar-
asitics, anticonvulsants and psychotropic drugs. Two RCTs
reported significantly higher mortality rates in the treatment
group. Only 69 (12%) of the RCTs stated there was a DSMB.
DSMBs terminated five RCTs and changed the protocol in one.
Conclusions Children participating in drug RCTs experi-
ence a significant amount and a wide range of ADRs.
DSMBs are needed to ensure the safety of paediatric
participants in clinical drug trials.
Keywords Paediatric clinical trials.Adverse drug reactions
(ADRs).Drug safety.Data safety monitoring boards
(DSMBs).Systematic review
Introduction
Recent changes in US and European drug regulation have
provided a stimulatory environment for paediatric clinical
drug trials to be performed [1, 2]. As a result, larger
numbers of paediatric clinical trials have been conducted
providing valuable information for the judicious use of
medicines in children [3–5]. However, when participating
in clinical trials, paediatric patients are exposed to a risk of
experiencing adverse drug reactions (ADRs). This is a
primary concern to parents, clinicians and regulatory
agencies due to the vulnerable nature of the paediatric
population and that participation of children in these trials
are via proxy consent of their caregivers. However,
surprisingly little work has attempted to shed light on the
toxicity experienced of paediatric participants in drug trials.
A review of >700 paediatric drug trials published between
1996 and 2002 found that ADRs occurred in more than a
third of the trials. Although 11% of the trials reported that
moderate or severe ADRs occurred, only 2% of the trials
mentioned that a data safety monitoring board (DSMB) was
formed to oversee the safety of the study [6]. This previous
study, however, was not a comprehensive systematic review
in that only one database (Medline) was used and trials in
the areas of oncology and HIV were excluded. We
therefore felt it was appropriate to perform a comprehen-
sive systematic review of drug toxicity within paediatric
drug randomised controlled trials (RCTs) published in
2007 [7].
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The method used to establish the database of paediatric drug
RCTs has been previously described [7]. Briefly, Medline,
Embase and Cochrane Collaboration Central Register data-
bases were searched electronically to systematically identify
RCTs published in 2007. Validated search strategies derived
from those developed by the Cochrane Collaboration [8]a n d
the Hedges Team [9] were used. The search was limited to
drug trials and involving paediatric patients. The resulting
Table 1 Number of RCTs where severe and moderate adverse drug reactions (ADRs) were detected
WHO ATC Drug Class SevereADR Percent
(%)
Moderate
ADR
Percent
(%)
Total number of
RCTs
Antineoplastic and immunomodulating agents 19 49 6 15 39
Cardiovascular system 2 15 1 8 13
Antiparasitic products,insecticides and repellents 6 13 1 2 45
Blood and blood-forming organs 2 13 2 13 15
Alimentary tract and metabolism 5 13 5 13 40
Systemic hormonal preparations,excluding sex hormones and
insulins
5 12 5 12 42
Anti-infectives for systemic use 9 9 20 21 97
Nervous system 12 8 15 10 144
Musculoskeletal system 1 5 2 10 20
Respiratory system 5 7 10 14 72
Dermatologicals 0 – 92 3 4 0
Genitourinary system and sex hormones 0 – 25 0 4
Sensory organs 0 – 11 0 1 0
Various 0 – 0 – 1
Total 66 11 79 14 582
WHO World Health Organisation, ATC Anatomical–Therapeutic–Chemical, RCT randomised controlled trials,
Table 2 Severe adverse drug ractions (ADRs) detected in 540 randomised controlled trials (RCTs) involving infants and children published in
2007
Severe ADRs Drug(s)
Hepatotoxicity Liposomal amphotericin B, anidulafungin, cytotoxic drugs
Convulsions Anidulafungin, antimalarials, levocetirizine
Suicidal ideation Levetiracetam, venlafaxine, bupropion, olanzapine, fluoxetine
Severe psychiatric symptoms Anticonvulsants: lamotrigine, topiramate, valproate, carbamazepine, gabapentin, lamotrigine,
oxcarbazepine
Cardiac arrhythmias Posaconazole, fluconazole, itraconazole, terbutaline
Cardiotoxicity Deferiprone, desferrioxamine, cytotoxic drugs
Bone marrow suppression e.g. neutropaenia,
thrombocytopaenia
Idebenone (Friedrich’s ataxia), gatifloxacin, cytotoxic drugs, liposomal amphotericin B,
anidulafungin
Intussusception Rotavirus vaccine
Bronchitis Inhaled zanamivir
Respiratory depression Valproate, diazepam, phenytoin, midazolam, ketamine, propofol, Idursulfase (MPS II/Hunter
syndrome)
Gastrointestinal bleeding Dexamethasone, ibuprofen
Hypoglycaemia Insulin, glimepiride, metformin
Nephrotoxicity Amifostine, liposomal amphotericin B, anidulafungin
Ototoxicity Liposomal amphotericin B, anidulafungin
Neurotoxicity Cytotoxic drugs
Secondary malignancies Cytotoxic drugs
Growth retardation Corticosteroids
190 Eur J Clin Pharmacol (2012) 68:189–194citations were hand searched, and full-text papers were
obtained for all studies deemed relevant. Supplementary
material was retrieved whenever available. Each RCT report
was carefully read to evaluate whether safety monitoring was
mentioned in the Methods section. Any mention of the
words safety, adverse effect/event/experience/reaction, side-/
unwanted effect, toxicity or any indication that adverse
events were monitored was noted. Whether any adverse
events (AEs) were detected was determined from carefully
reading the Results section or supplementary information
when available. The definition and classification of AEs used
in this study were based on guidelines produced by the
European Agency for the Evaluation of Medicinal Products
(EMA) and the International Conference for Harmonisation
(ICH) [6]. An AE was defined as any untoward medical
occurrence in a patient or clinical investigation participant
administered a pharmaceutical product and did not
necessarily need to have a causal relationship with this
treatment. AEs are classified as serious, significant or mild
according to the following groupings [6]:
1. Serious AE (SAE): any untoward medical occurrences
at any dose that results in death, is life-threatening,
requires in-patient hospitalisation or prolongation of
existing hospitalisation, results in persistent or signifi-
cant disability/incapacity, or is a congenital anomaly/
birth defect.
2. Significant AE: haematological and other laboratory
abnormalities and any AE that led to an intervention,
including withdrawal of drug treatment, dose reduction
or significant additional concomitant therapy.
3. Mild AE: any AE occurring that did not need any
intervention.
The number of papers reporting any mortality was
noted. Any trial that was discontinued was also noted and
the reason for discontinuation determined. The most
serious AE in each report was determined and used to
stratify the RCTs. All trials reporting a serious AE were
further reviewed by two paediatric clinical pharmacolo-
gists (IC and HMS) independently to judge whether any of
t h es e r i o u sA E sw e r ep o s s i b l eA D R s .T h ed e c i s i o nb y
each reviewer was noted, and when there was disagree-
ment, a consensus was obtained from joint discussions. An
ADR was defined as an AE thought to be linked in either
time or dose to a drug given to that patient. Each RCT
included in this study was assessed as to whether a
possible ADR had occurred and were classified according
to the highest severity of ADR in the report. The
classification used for ADRs was as follows [6, 10]:
1. Severe: fatal or potentially life threatening or causing
permanent disability.
2. Moderate: requiring treatment or prolonging stay in
hospital.
3. Mild: no treatment required and no effect on length of
stay in hospital.
In RCTs where ADRs were detected, the following
characteristics were analysed:
1. The World Health Organisation (WHO) Anatomical–
Therapeutic–Chemical (ATC) classification category.
2. Population age group being studied.
3. Sample size of the study.
All RCT reports were checked to determine whether a
DSMB or an independent safety evaluator was involved in
overseeing the trial. In addition, it was determined whether
any interim analysis [11] was performed or whether a
stopping rule [12] for the trials was designated. These were
assumed to be present whenever a DSMB was mentioned.
Data were analysed and stored using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). Categorical variables are
described with frequencies or percentages. Fisher’s exact test
was used to calculate p values for differences in proportions.
Results
Safety data from 582 paediatric RCTs were analysed.
Epidemiological and methodological characteristics of these
trials have been previously described [7]. Five hundred and
forty trials involved infants and children, and 42 (7%)
involved neonates. Approximately two thirds of the trials
(375, 64%) mentioned safety monitoring in the Methods
Table 3 Severe adverse drug
reactions (ADRs) detected in 42
neonatal randomised
controlled trials (RCTs)
published in 2007
Severe ADRs Drug(s)
Intraventricular haemorrhage/periventricular leukomalacia Inhaled nitric oxide
Fatal central nervous system bleeding Drotrecogin Alfa
Necrotising enterocolitis Ibuprofen, indomethacin, immunoglobulin
Pulmonary haemorrhage Ibuprofen, indomethacin, immunoglobulin
Gastrointestinal perforation Hydrocortisone
Hypertension Prednisolone
Eur J Clin Pharmacol (2012) 68:189–194 191section. The majority of the trials (463, 80%) reported on
AEs including studies stating that no AEs had occurred.
Over one third of the trials (210, 36%) reported that an SAE
had occurred in the trial. Eighty-seven RCTs (15%) reported
that mortality had occurred during the trial. Twenty-two
RCTs involving cytotoxic drugs (56% of the total number of
oncology RCTs) reported mortalities. Six of the 13 trials
involving cardiovascular drugs (46%) reported mortalities.
ADRs were considered to have occurred in more than half
of the trials (305, 52%), whereas the remainder were either
determined to have experienced no ADRs (141, 24%) or
were found to be impossible to judge whether an ADR had
occurred (136, 23%). In just over a quarter of the trials (160,
28%), only mild ADRs occurred. Moderate ADRs occurred
in79(14%) RCTs.SevereADRswerefound in66/582(11%)
of RCTs involving children. Severe ADRs occurred most
frequently in oncology RCTs (49%, 19/39 trials) and
cardiovascular drug RCTs (15%, 2/13 trials) (Table 1).
The severe ADRs detected included most of the major
organ systems and a wide range of medicines. The severe
ADRs detected and the drugs involved are shown in Table 2
(infants and children) and Table 3 (neonatal). There was no
significant difference between the proportions of neonatal
and nonneonatal RCTs in which severe ADRs were
detected: 7/42 (17%) vs 59/540 (11%, p=0.31).
Only 69 (12%) RCTs documented that a DSMB or
independent safety evaluator was involved. An additional
four trials mentioned either termination rules or that interim
analysis was done but without specifically mentioning the
presence of a DSMB. Significantly more trials that
mentioned an SAE occurring documented that a DSMB
was present in comparison to trials with no SAEs (55/210
vs 14/372 trials, p<0.05). DSMBs terminated five RCTs
and changed the protocol of one after an episode of toxicity
[13]. Three RCTs were terminated due to the risk of toxicity
[14–16], one was terminated for lack of efficacy [17] and
another for administrative reasons [18] (Table 4). Four of
these trials involved neonates.
Two RCTs reported significantly higher mortality rates in
the treatment group. One of these involved chemotherapy for
germ-cell tumours and was terminated by the DSMB [15].
The other was a trial comparing magnesium sulphate
infusions to placebo in 499 patients 14 years of age or older
who were admitted to a trauma centre with traumatic brain
injury [19]. The trial involving magnesium sulphate did not
appear to have a DSMB, and it is difficult to establish the
number of paediatric patients who died within this trial.
Discussion
The safety of medicines given to children has received
significant attention in recent years [20]. The safe and
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192 Eur J Clin Pharmacol (2012) 68:189–194effective use of paediatric medications requires adequate
information gained from clinical trials involving children
themselves [21]. When this fact was highlighted by health
professionals, governments were prompted to take regulatory
action and provide incentives towards the drug industry who
are the main sponsors of drug research [22]. This has led to
large numbers of children participating in drug studies,
including RCTs [7]. In RCTs in which children are involved,
the potential of harm caused by ADRs is a primary concern
for parents, investigators, regulators and sponsors. ADRs
affect a significant number of patients being treated with
drugs. A large meta-analysis found that 10.9% of all
hospitalised patients (both adult and paediatric) experience
a severe ADR, and fatal ADRs were between the fourth and
sixth leading cause of death [23].
This review demonstrates that ADRs occurred in more
than half (52%) of drug RCTs involving paediatric patients
that were published in 2007. It is important to note that this
percentage does not indicate the risk of ADRs for children
taking part in RCTs but merely the proportion of trials in
which ADRs were detected [6]. Previous studies have
shown that the overall incidence of ADRs in the paediatric
population is 634 per million children per year [24] and
approximately 10% for hospitalised children [25]. It is
important that ADRs are assessed in the setting of a trial so
they can be established before the medicine is used in
clinical practice.
Significant drug toxicity (moderate or severe ADRs) was
detected in a quarter (25%) of the trials in our study. This is
higher than previously reported (11%) [6]. This study is the
first systematic review published of safety in paediatric
clinical trials. Previous reviews have not been systematic in
that they have either not included all paediatric RCTs or not
used more than one database [6, 26] to capture all the
available evidence. In our study, antineoplastic drug trials
accounted for roughly one third (19/66) of the RCTs in
which severe ADRs were detected. This is not surprising,
as cytotoxic drugs—because of their mode of action—are
invariably associated with significant drug toxicity.
Clinical trials of cytotoxic drugs are essential. It is
important, however, that parents and children are aware
of the risk for drug toxicity within a clinical trial and/or
a treatment regime. This can then be weighed against
the child’s clinical condition. In a large number of RCTs
in this study, it was impossible to ascertain whether an
ADR had occurred from the safety data reported.
Twenty percent of the RCTs in our database did not
report any safety data. The inadequate reporting of
safety data from RCTs in both adults and children has
been noted previously [26–28]. RCTs are usually not
powered to detect ADRs [29]. Despite this, it is important
that RCTs adequately and transparently report safety data.
This then allows for meta analysis later when suitable and
gives clinicians appropriate evidence for their prescribing
decisions.
There is persisting concern that very few paediatric
RCTs in our review documented that DSMBs were formed
to oversee the trial. The studies in which DSMBs
intervened clearly demonstrated the vital role they play in
ensuring the safety of the participating patients. The latest
guidelines on ethical conduct of paediatric clinical trials
now state that DSMBs should be created for all phase 3
clinical trials involving paediatric patients [30]. Of the 582
RCTs published in 2007, five were terminated by a DSMB.
Unfortunately, not all trials are published and, where a trial
has been terminated or there is significant toxicity, authors
are probably less likely to publish their findings [31].
Therefore, safety issues must be a key consideration at
the design stage of a clinical trial. Stopping rules need to be
determined at the outset, with a termination plan in place in
case of severe ADRs occurring [32]. An independent and
effective DSMB should be instituted. There are clear
guidelines available as to who should be members of a
DSMB and their roles [33].
Three out of the five terminated trials were neonatal
RCTs. Although neonatal RCTs constituted only 7% of the
trials in our database [7], severe ADRs were prominent in
the neonatal RCTs reviewed. It is recognised that the
physiology of the neonate is very different from that of
older children and may predispose to certain drug toxicities
[34]; however, more research is needed to elucidate whether
neonates are more at risk of ADRs than are older children.
In conclusion, findings from this study confirmed that
moderate and severe ADRs occur in 25% of RCTs involving
children.Unfortunately,veryfewoftheseRCTs documentthe
presence of a DSMB. All clinical trials involving the
paediatric population should have a designated DSMB. The
role of the DSMB is crucial in protecting children participat-
inginRCTs,especiallyinthecurrentsituationwherethereisa
growing effort to formally evaluate drugs in children to
provide them with safe and effective medicines.
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medium, provided the original author(s) and source are credited.
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